Identification of nine new susceptibility loci for endometrial cancer

Tracy A. O’Mara; Dylan M. Glubb; Frederic Amant; Daniela Annibali; Katie Ashton; John Attia; Paul L. Auer; Matthias W. Beckmann; Amanda Black; Manjeet K. Bolla; Hiltrud Brauch; Hermann Brenner; Louise Brinton; Daniel D. Buchanan; Barbara Burwinkel; Jenny Chang-Claude; Stephen J. Chanock; Chu Chen; Maxine M. Chen; Timothy H.T. Cheng; Christine L. Clarke; Mark Clendenning; Linda S. Cook; Fergus J. Couch; Angela Cox; Marta Crous-Bous; Kamila Czene; Felix Day; Joe Dennis; Jeroen Depreeuw; Jennifer Anne Doherty; Thilo Dörk; Sean C. Dowdy; Matthias Dürst; Arif B. Ekici; Peter A. Fasching; Brooke L. Fridley; Christine M. Friedenreich; Lin Fritschi; Jenny Fung; Montserrat García-Closas; Mia M. Gaudet; Graham G. Giles; Ellen L. Goode; Maggie Gorman; Christopher A. Haiman; Per Hall; Susan E. Hankison; Catherine S. Healey; Alexander Hein; Peter Hillemanns; Shirley Hodgson; Erling A. Hoivik; Elizabeth G. Holliday; John L. Hopper; David J. Hunter; Angela Jones; Camilla Krakstad; Vessela N. Kristensen; Diether Lambrechts; Loic Le Marchand; Xiaolin Liang; Annika Lindblom; Jolanta Lissowska; Jirong Long; Lingeng Lu; Anthony M. Magliocco; Lynn Martin; Mark McEvoy; Alfons Meindl; Kyriaki Michailidou; Roger L. Milne; Miriam Mints; Grant W. Montgomery; Rami Nassir; Håkan Olsson; Irene Orlow; Geoffrey Otton; Claire Palles; John R.B. Perry; Julian Peto; Loreall Pooler; Jennifer Prescott; Tony Proietto; Timothy R. Rebbeck; Harvey A. Risch; Peter A.W. Rogers; Matthias Rübner; Ingo Runnebaum; Carlotta Sacerdote; Gloria E. Sarto; Fredrick Schumacher; Rodney J. Scott; V. Wendy Setiawan; Mitul Shah; Xin Sheng; Xiao Ou Shu; Melissa C. Southey; Anthony J. Swerdlow; Emma Tham; Jone Trovik; Constance Turman; Jonathan P. Tyrer; Celine Vachon; David VanDen Berg; Adriaan Vanderstichele; Zhaoming Wang; Penelope M. Webb; Nicolas Wentzensen; Henrica M.J. Werner; Stacey J. Winham; Alicja Wolk; Lucy Xia; Yong Bing Xiang; Hannah P. Yang; Herbert Yu; Wei Zheng; Paul D.P. Pharoah; Alison M. Dunning; Peter Kraft; Immaculata De Vivo; Ian Tomlinson; Douglas F. Easton; Amanda B. Spurdle; Deborah J. Thompson

doi:10.1038/s41467-018-05427-7

Identification of nine new susceptibility loci for endometrial cancer

Tracy A. O’Mara, Dylan M. Glubb, Frederic Amant, Daniela Annibali, Katie Ashton, John Attia, Paul L. Auer, Matthias W. Beckmann, Amanda Black, Manjeet K. Bolla, Hiltrud Brauch, Hermann Brenner, Louise Brinton, Daniel D. Buchanan, Barbara Burwinkel, Jenny Chang-Claude, Stephen J. Chanock, Chu Chen, Maxine M. Chen, Timothy H.T. ChengChristine L. Clarke, Mark Clendenning, Linda S. Cook, Fergus J. Couch, Angela Cox, Marta Crous-Bous, Kamila Czene, Felix Day, Joe Dennis, Jeroen Depreeuw, Jennifer Anne Doherty, Thilo Dörk, Sean C. Dowdy, Matthias Dürst, Arif B. Ekici, Peter A. Fasching, Brooke L. Fridley, Christine M. Friedenreich, Lin Fritschi, Jenny Fung, Montserrat García-Closas, Mia M. Gaudet, Graham G. Giles, Ellen L. Goode, Maggie Gorman, Christopher A. Haiman, Per Hall, Susan E. Hankison, Catherine S. Healey, Alexander Hein, Peter Hillemanns, Shirley Hodgson, Erling A. Hoivik, Elizabeth G. Holliday, John L. Hopper, David J. Hunter, Angela Jones, Camilla Krakstad, Vessela N. Kristensen, Diether Lambrechts, Loic Le Marchand, Xiaolin Liang, Annika Lindblom, Jolanta Lissowska, Jirong Long, Lingeng Lu, Anthony M. Magliocco, Lynn Martin, Mark McEvoy, Alfons Meindl, Kyriaki Michailidou, Roger L. Milne, Miriam Mints, Grant W. Montgomery, Rami Nassir, Håkan Olsson, Irene Orlow, Geoffrey Otton, Claire Palles, John R.B. Perry, Julian Peto, Loreall Pooler, Jennifer Prescott, Tony Proietto, Timothy R. Rebbeck, Harvey A. Risch, Peter A.W. Rogers, Matthias Rübner, Ingo Runnebaum, Carlotta Sacerdote, Gloria E. Sarto, Fredrick Schumacher, Rodney J. Scott, V. Wendy Setiawan, Mitul Shah, Xin Sheng, Xiao Ou Shu, Melissa C. Southey, Anthony J. Swerdlow, Emma Tham, Jone Trovik, Constance Turman, Jonathan P. Tyrer, Celine Vachon, David VanDen Berg, Adriaan Vanderstichele, Zhaoming Wang, Penelope M. Webb, Nicolas Wentzensen, Henrica M.J. Werner, Stacey J. Winham, Alicja Wolk, Lucy Xia, Yong Bing Xiang, Hannah P. Yang, Herbert Yu, Wei Zheng, Paul D.P. Pharoah, Alison M. Dunning, Peter Kraft, Immaculata De Vivo, Ian Tomlinson, Douglas F. Easton, Amanda B. Spurdle, Deborah J. Thompson

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

Endometrial cancer is the most commonly diagnosed cancer of the female reproductive tract in developed countries. Through genome-wide association studies (GWAS), we have previously identified eight risk loci for endometrial cancer. Here, we present an expanded meta-analysis of 12,906 endometrial cancer cases and 108,979 controls (including new genotype data for 5624 cases) and identify nine novel genome-wide significant loci, including a locus on 12q24.12 previously identified by meta-GWAS of endometrial and colorectal cancer. At five loci, expression quantitative trait locus (eQTL) analyses identify candidate causal genes; risk alleles at two of these loci associate with decreased expression of genes, which encode negative regulators of oncogenic signal transduction proteins (SH2B3 (12q24.12) and NF1 (17q11.2)). In summary, this study has doubled the number of known endometrial cancer risk loci and revealed candidate causal genes for future study.

Original language	English (US)
Article number	3166
Journal	Nature communications
Volume	9
Issue number	1
DOIs	https://doi.org/10.1038/s41467-018-05427-7
State	Published - Dec 1 2018

ASJC Scopus subject areas

Chemistry(all)
Biochemistry, Genetics and Molecular Biology(all)
General
Physics and Astronomy(all)

Access to Document

10.1038/s41467-018-05427-7

Cite this

O’Mara, T. A., Glubb, D. M., Amant, F., Annibali, D., Ashton, K., Attia, J., Auer, P. L., Beckmann, M. W., Black, A., Bolla, M. K., Brauch, H., Brenner, H., Brinton, L., Buchanan, D. D., Burwinkel, B., Chang-Claude, J., Chanock, S. J., Chen, C., Chen, M. M., ... Thompson, D. J. (2018). Identification of nine new susceptibility loci for endometrial cancer. Nature communications, 9(1), [3166]. https://doi.org/10.1038/s41467-018-05427-7

O’Mara, TA, Glubb, DM, Amant, F, Annibali, D, Ashton, K, Attia, J, Auer, PL, Beckmann, MW, Black, A, Bolla, MK, Brauch, H, Brenner, H, Brinton, L, Buchanan, DD, Burwinkel, B, Chang-Claude, J, Chanock, SJ, Chen, C, Chen, MM, Cheng, THT, Clarke, CL, Clendenning, M, Cook, LS, Couch, FJ, Cox, A, Crous-Bous, M, Czene, K, Day, F, Dennis, J, Depreeuw, J, Doherty, JA, Dörk, T, Dowdy, SC, Dürst, M, Ekici, AB, Fasching, PA, Fridley, BL, Friedenreich, CM, Fritschi, L, Fung, J, García-Closas, M, Gaudet, MM, Giles, GG, Goode, EL, Gorman, M, Haiman, CA, Hall, P, Hankison, SE, Healey, CS, Hein, A, Hillemanns, P, Hodgson, S, Hoivik, EA, Holliday, EG, Hopper, JL, Hunter, DJ, Jones, A, Krakstad, C, Kristensen, VN, Lambrechts, D, Marchand, LL, Liang, X, Lindblom, A, Lissowska, J, Long, J, Lu, L, Magliocco, AM, Martin, L, McEvoy, M, Meindl, A, Michailidou, K, Milne, RL, Mints, M, Montgomery, GW, Nassir, R, Olsson, H, Orlow, I, Otton, G, Palles, C, Perry, JRB, Peto, J, Pooler, L, Prescott, J, Proietto, T, Rebbeck, TR, Risch, HA, Rogers, PAW, Rübner, M, Runnebaum, I, Sacerdote, C, Sarto, GE, Schumacher, F, Scott, RJ, Setiawan, VW, Shah, M, Sheng, X, Shu, XO, Southey, MC, Swerdlow, AJ, Tham, E, Trovik, J, Turman, C, Tyrer, JP, Vachon, C, VanDen Berg, D, Vanderstichele, A, Wang, Z, Webb, PM, Wentzensen, N, Werner, HMJ, Winham, SJ, Wolk, A, Xia, L, Xiang, YB, Yang, HP, Yu, H, Zheng, W, Pharoah, PDP, Dunning, AM, Kraft, P, De Vivo, I, Tomlinson, I, Easton, DF, Spurdle, AB & Thompson, DJ 2018, 'Identification of nine new susceptibility loci for endometrial cancer', Nature communications, vol. 9, no. 1, 3166. https://doi.org/10.1038/s41467-018-05427-7

@article{0477091b168246bd8c0017c90bee2049,

title = "Identification of nine new susceptibility loci for endometrial cancer",

abstract = "Endometrial cancer is the most commonly diagnosed cancer of the female reproductive tract in developed countries. Through genome-wide association studies (GWAS), we have previously identified eight risk loci for endometrial cancer. Here, we present an expanded meta-analysis of 12,906 endometrial cancer cases and 108,979 controls (including new genotype data for 5624 cases) and identify nine novel genome-wide significant loci, including a locus on 12q24.12 previously identified by meta-GWAS of endometrial and colorectal cancer. At five loci, expression quantitative trait locus (eQTL) analyses identify candidate causal genes; risk alleles at two of these loci associate with decreased expression of genes, which encode negative regulators of oncogenic signal transduction proteins (SH2B3 (12q24.12) and NF1 (17q11.2)). In summary, this study has doubled the number of known endometrial cancer risk loci and revealed candidate causal genes for future study.",

author = "O{\textquoteright}Mara, {Tracy A.} and Glubb, {Dylan M.} and Frederic Amant and Daniela Annibali and Katie Ashton and John Attia and Auer, {Paul L.} and Beckmann, {Matthias W.} and Amanda Black and Bolla, {Manjeet K.} and Hiltrud Brauch and Hermann Brenner and Louise Brinton and Buchanan, {Daniel D.} and Barbara Burwinkel and Jenny Chang-Claude and Chanock, {Stephen J.} and Chu Chen and Chen, {Maxine M.} and Cheng, {Timothy H.T.} and Clarke, {Christine L.} and Mark Clendenning and Cook, {Linda S.} and Couch, {Fergus J.} and Angela Cox and Marta Crous-Bous and Kamila Czene and Felix Day and Joe Dennis and Jeroen Depreeuw and Doherty, {Jennifer Anne} and Thilo D{\"o}rk and Dowdy, {Sean C.} and Matthias D{\"u}rst and Ekici, {Arif B.} and Fasching, {Peter A.} and Fridley, {Brooke L.} and Friedenreich, {Christine M.} and Lin Fritschi and Jenny Fung and Montserrat Garc{\'i}a-Closas and Gaudet, {Mia M.} and Giles, {Graham G.} and Goode, {Ellen L.} and Maggie Gorman and Haiman, {Christopher A.} and Per Hall and Hankison, {Susan E.} and Healey, {Catherine S.} and Alexander Hein and Peter Hillemanns and Shirley Hodgson and Hoivik, {Erling A.} and Holliday, {Elizabeth G.} and Hopper, {John L.} and Hunter, {David J.} and Angela Jones and Camilla Krakstad and Kristensen, {Vessela N.} and Diether Lambrechts and Marchand, {Loic Le} and Xiaolin Liang and Annika Lindblom and Jolanta Lissowska and Jirong Long and Lingeng Lu and Magliocco, {Anthony M.} and Lynn Martin and Mark McEvoy and Alfons Meindl and Kyriaki Michailidou and Milne, {Roger L.} and Miriam Mints and Montgomery, {Grant W.} and Rami Nassir and H{\aa}kan Olsson and Irene Orlow and Geoffrey Otton and Claire Palles and Perry, {John R.B.} and Julian Peto and Loreall Pooler and Jennifer Prescott and Tony Proietto and Rebbeck, {Timothy R.} and Risch, {Harvey A.} and Rogers, {Peter A.W.} and Matthias R{\"u}bner and Ingo Runnebaum and Carlotta Sacerdote and Sarto, {Gloria E.} and Fredrick Schumacher and Scott, {Rodney J.} and Setiawan, {V. Wendy} and Mitul Shah and Xin Sheng and Shu, {Xiao Ou} and Southey, {Melissa C.} and Swerdlow, {Anthony J.} and Emma Tham and Jone Trovik and Constance Turman and Tyrer, {Jonathan P.} and Celine Vachon and {VanDen Berg}, David and Adriaan Vanderstichele and Zhaoming Wang and Webb, {Penelope M.} and Nicolas Wentzensen and Werner, {Henrica M.J.} and Winham, {Stacey J.} and Alicja Wolk and Lucy Xia and Xiang, {Yong Bing} and Yang, {Hannah P.} and Herbert Yu and Wei Zheng and Pharoah, {Paul D.P.} and Dunning, {Alison M.} and Peter Kraft and {De Vivo}, Immaculata and Ian Tomlinson and Easton, {Douglas F.} and Spurdle, {Amanda B.} and Thompson, {Deborah J.}",

note = "Funding Information: We thank the many individuals who participated in this study and the numerous institutions and their staff who supported recruitment, detailed in full in the Supplementary Information. The iCOGS and OncoArray endometrial cancer analysis were supported by NHMRC project grants (ID#1031333 and ID#1109286) to A.B.S., D.F.E., A.M.D., D.J.T., and I.T. A.B.S. (APP1061779), P.M.W., and T.A.O{\textquoteright}. M. (APP1111246) are supported by the NHMRC Fellowship scheme. A.M.D. was supported by the Joseph Mitchell Trust. I.T. is supported by Cancer Research UK and the Oxford Comprehensive Biomedical Research Center. Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework Programme under grant agreement no. 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A10710, C12292/A11174, C1281/ A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112—the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund. OncoArray genotyping of ECAC cases was performed with the generous assistance of the Ovarian Cancer Association Consortium (OCAC). We particularly thank the efforts of Cathy Phelan. The OCAC OncoArray genotyping project was funded through grants from the US National Institutes of Health (CA1X01HG007491-01 (Christopher I. Amos), U19-CA148112 (Thomas A. Sellers), R01-CA149429 (Catherine M. Phelan), and R01-CA058598 (Marc T. Goodman)); Canadian Institutes of Health Research (MOP-86727 (Linda E. Kelemen)); and the Ovarian Cancer Research Fund (Andrew Berchuck). CIDR genotyping for the Oncoarray was conducted under contract 268201200008I. OncoArray genotyping of the BCAC controls was funded by Genome Canada Grant GPH-129344, NIH Grant U19 CA148065, and Cancer UK Grant C1287/A16563. ANECS recruitment was supported by project grants from the NHMRC (ID#339435), The Cancer Council Queensland (ID#4196615), and Cancer Council Tasmania (ID#403031 and ID#457636). SEARCH recruitment was funded by a programme grant from Cancer Research UK (C490/A10124). Stage 1 and stage 2 case genotyping was supported by the NHMRC (ID#552402, ID#1031333). Control data were generated by the Wellcome Trust Case Control Consortium (WTCCC), and a full list of the investigators who contributed to the generation of the data is available from the WTCCC website. We acknowledge use of DNA from the British 1958 Birth Cohort collection, funded by the Medical Research Council grant G0000934 and the Wellcome Trust grant 068545/Z/02—funding for this project was provided by the Wellcome Trust under award 085475. NSECG was supported by the EU FP7 CHIBCHA grant, Wellcome Trust Centre for Human Genetics Core Grant 090532/Z/09Z, and CORGI was funded by Cancer Research UK. We thank Nick Martin, Dale Nyholt, and Anjali Henders for access to GWAS data from QIMR Controls. Recruitment of the QIMR controls was supported by the NHMRC. The University of Newcastle, the Gladys M Brawn Senior Research Fellowship scheme, The Vincent Fairfax Family Foundation, the Hunter Medical Research Institute, and the Hunter Area Pathology Service all contributed toward the costs of establishing the Hunter Community Study. The Bavarian Endometrial Cancer Study (BECS) was partly funded by the ELAN fund of the University of Erlangen. The Hannover-Jena Endometrial Cancer Study was partly supported by the Rudolf Bartling Foundation. The Leuven Endometrium Study (LES) was supported by the Verelst Foundation for endometrial cancer. The Mayo Endometrial Cancer Study (MECS) and Mayo controls (MAY) were supported by grants from the National Cancer Institute of United States Public Health Service (R01 CA122443, P30 CA15083, P50 CA136393, and GAME-ON the NCI Cancer Post-GWAS Initiative U19 CA148112), the Fred C and Katherine B Andersen Foundation, the Mayo Foundation, and the Ovarian Cancer Research Fund with support of the Smith family, in memory of Kathryn Sladek Smith. MoMaTEC received financial support from a Helse Vest Grant, the University of Bergen, Melzer Foundation, The Norwegian Cancer Society (Harald Andersens legat), The Research Council of Norway and Haukeland University Hospital. The Newcastle Endometrial Cancer Study (NECS) acknowledges contributions from the University of Newcastle, The NBN Children{\textquoteright}s Cancer Research Group, Ms. Jennie Thomas, and the Hunter Medical Research Institute. RENDOCAS was supported through the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet (numbers: 20110222, 20110483, 20110141 and DF07015), The Swedish Labor Market Insurance (number 100069), and The Swedish Cancer Society (number 11 0439). The Cancer Hormone Replacement Epidemiology in Sweden Study (CAHRES, formerly called The Singapore and Swedish Breast/Endometrial Cancer Study; SASBAC) was supported by funding from the Agency for Science, Technology and Research of Singapore (A*STAR), the US National Institutes of Health, and the Susan G. Komen Breast Cancer Foundation. The WHI program is funded by the National Heart, Lung, and Blood Institute, the US National Institutes of Health, and the US Department of Health and Human Services (HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C). This work was also funded by NCI U19 CA148065-01. The Nurses{\textquoteright} Health Study (NHS) is supported by the NCI, NIH Grants Number UM1 CA186107, P01 CA087969, R01 CA49449, 1R01 CA134958, and 2R01 CA082838. We thank the participants and staff of the Nurses{\textquoteright} Health Study for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, and WY. We assume full responsibility for analyses and interpretation of these data. We also thank Channing Division of Network Medicine, Department of Medicine, Brigham and Women{\textquoteright}s Hospital, and Harvard Medical School. Finally, we also acknowledge Pati Soule and Hardeep Ranu for their laboratory assistance. The Connecticut Endometrial Cancer Study was supported by NCI, NIH Grant Number RO1CA98346. The Fred Hutchinson Cancer Research Center (FHCRC) is supported by NCI, NIH Grant Number NIH RO1 CA105212, RO1 CA 87538, RO1 CA75977, RO3 CA80636, NO1 HD23166, R35 CA39779, KO5 CA92002, and funds from the Fred Hutchinson Cancer Research Center. The Multiethnic Cohort Study (MEC) is supported by the NCI, NHI Grants Number CA54281, CA128008, and 2R01 CA082838. The California Teachers Study (CTS) is supported by NCI, NIH Grant Number 2R01 CA082838, R01 CA91019, and R01 CA77398, and contract 97-10500 from the California Breast Cancer Research Fund. The Polish Endometrial Cancer Study (PECS) is supported by the Intramural Research Program of the NCI. The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) is supported by the Extramural and the Intramural Research Programs of the NCI. The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts, HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C. This manuscript was prepared in collaboration with investigators of the WHI, and has been reviewed and/or approved by the Women{\textquoteright}s Health Initiative (WHI). WHI investigators are listed at https://www.whi. org/researchers/Documents%20%20Write%20a%20Paper/WHI%20Investigator% 20Short%20List.pdf. The Breast Cancer Association Consortium (BCAC) is funded by Cancer Research UK (C1287/A10118, C1287/A12014). The Ovarian Cancer Association Consortium (OCAC) is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07), and the UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge. This research has been conducted using the UK Biobank Resource under applications 5122 and 9797. We gratefully acknowledge the TCGA endometrial cancer consortium for providing samples, tissues, data processing, and making data and results available. Additional funding for individual control groups is detailed in the Supplementary Information. Publisher Copyright: {\textcopyright} 2018, The Author(s).",

year = "2018",

month = dec,

day = "1",

doi = "10.1038/s41467-018-05427-7",

language = "English (US)",

volume = "9",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Identification of nine new susceptibility loci for endometrial cancer

AU - O’Mara, Tracy A.

AU - Glubb, Dylan M.

AU - Amant, Frederic

AU - Annibali, Daniela

AU - Ashton, Katie

AU - Attia, John

AU - Auer, Paul L.

AU - Beckmann, Matthias W.

AU - Black, Amanda

AU - Bolla, Manjeet K.

AU - Brauch, Hiltrud

AU - Brenner, Hermann

AU - Brinton, Louise

AU - Buchanan, Daniel D.

AU - Burwinkel, Barbara

AU - Chang-Claude, Jenny

AU - Chanock, Stephen J.

AU - Chen, Chu

AU - Chen, Maxine M.

AU - Cheng, Timothy H.T.

AU - Clarke, Christine L.

AU - Clendenning, Mark

AU - Cook, Linda S.

AU - Couch, Fergus J.

AU - Cox, Angela

AU - Crous-Bous, Marta

AU - Czene, Kamila

AU - Day, Felix

AU - Dennis, Joe

AU - Depreeuw, Jeroen

AU - Doherty, Jennifer Anne

AU - Dörk, Thilo

AU - Dowdy, Sean C.

AU - Dürst, Matthias

AU - Ekici, Arif B.

AU - Fasching, Peter A.

AU - Fridley, Brooke L.

AU - Friedenreich, Christine M.

AU - Fritschi, Lin

AU - Fung, Jenny

AU - García-Closas, Montserrat

AU - Gaudet, Mia M.

AU - Giles, Graham G.

AU - Goode, Ellen L.

AU - Gorman, Maggie

AU - Haiman, Christopher A.

AU - Hall, Per

AU - Hankison, Susan E.

AU - Healey, Catherine S.

AU - Hein, Alexander

AU - Hillemanns, Peter

AU - Hodgson, Shirley

AU - Hoivik, Erling A.

AU - Holliday, Elizabeth G.

AU - Hopper, John L.

AU - Hunter, David J.

AU - Jones, Angela

AU - Krakstad, Camilla

AU - Kristensen, Vessela N.

AU - Lambrechts, Diether

AU - Marchand, Loic Le

AU - Liang, Xiaolin

AU - Lindblom, Annika

AU - Lissowska, Jolanta

AU - Long, Jirong

AU - Lu, Lingeng

AU - Magliocco, Anthony M.

AU - Martin, Lynn

AU - McEvoy, Mark

AU - Meindl, Alfons

AU - Michailidou, Kyriaki

AU - Milne, Roger L.

AU - Mints, Miriam

AU - Montgomery, Grant W.

AU - Nassir, Rami

AU - Olsson, Håkan

AU - Orlow, Irene

AU - Otton, Geoffrey

AU - Palles, Claire

AU - Perry, John R.B.

AU - Peto, Julian

AU - Pooler, Loreall

AU - Prescott, Jennifer

AU - Proietto, Tony

AU - Rebbeck, Timothy R.

AU - Risch, Harvey A.

AU - Rogers, Peter A.W.

AU - Rübner, Matthias

AU - Runnebaum, Ingo

AU - Sacerdote, Carlotta

AU - Sarto, Gloria E.

AU - Schumacher, Fredrick

AU - Scott, Rodney J.

AU - Setiawan, V. Wendy

AU - Shah, Mitul

AU - Sheng, Xin

AU - Shu, Xiao Ou

AU - Southey, Melissa C.

AU - Swerdlow, Anthony J.

AU - Tham, Emma

AU - Trovik, Jone

AU - Turman, Constance

AU - Tyrer, Jonathan P.

AU - Vachon, Celine

AU - VanDen Berg, David

AU - Vanderstichele, Adriaan

AU - Wang, Zhaoming

AU - Webb, Penelope M.

AU - Wentzensen, Nicolas

AU - Werner, Henrica M.J.

AU - Winham, Stacey J.

AU - Wolk, Alicja

AU - Xia, Lucy

AU - Xiang, Yong Bing

AU - Yang, Hannah P.

AU - Yu, Herbert

AU - Zheng, Wei

AU - Pharoah, Paul D.P.

AU - Dunning, Alison M.

AU - Kraft, Peter

AU - De Vivo, Immaculata

AU - Tomlinson, Ian

AU - Easton, Douglas F.

AU - Spurdle, Amanda B.

AU - Thompson, Deborah J.

N1 - Funding Information: We thank the many individuals who participated in this study and the numerous institutions and their staff who supported recruitment, detailed in full in the Supplementary Information. The iCOGS and OncoArray endometrial cancer analysis were supported by NHMRC project grants (ID#1031333 and ID#1109286) to A.B.S., D.F.E., A.M.D., D.J.T., and I.T. A.B.S. (APP1061779), P.M.W., and T.A.O’. M. (APP1111246) are supported by the NHMRC Fellowship scheme. A.M.D. was supported by the Joseph Mitchell Trust. I.T. is supported by Cancer Research UK and the Oxford Comprehensive Biomedical Research Center. Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework Programme under grant agreement no. 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A10710, C12292/A11174, C1281/ A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112—the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund. OncoArray genotyping of ECAC cases was performed with the generous assistance of the Ovarian Cancer Association Consortium (OCAC). We particularly thank the efforts of Cathy Phelan. The OCAC OncoArray genotyping project was funded through grants from the US National Institutes of Health (CA1X01HG007491-01 (Christopher I. Amos), U19-CA148112 (Thomas A. Sellers), R01-CA149429 (Catherine M. Phelan), and R01-CA058598 (Marc T. Goodman)); Canadian Institutes of Health Research (MOP-86727 (Linda E. Kelemen)); and the Ovarian Cancer Research Fund (Andrew Berchuck). CIDR genotyping for the Oncoarray was conducted under contract 268201200008I. OncoArray genotyping of the BCAC controls was funded by Genome Canada Grant GPH-129344, NIH Grant U19 CA148065, and Cancer UK Grant C1287/A16563. ANECS recruitment was supported by project grants from the NHMRC (ID#339435), The Cancer Council Queensland (ID#4196615), and Cancer Council Tasmania (ID#403031 and ID#457636). SEARCH recruitment was funded by a programme grant from Cancer Research UK (C490/A10124). Stage 1 and stage 2 case genotyping was supported by the NHMRC (ID#552402, ID#1031333). Control data were generated by the Wellcome Trust Case Control Consortium (WTCCC), and a full list of the investigators who contributed to the generation of the data is available from the WTCCC website. We acknowledge use of DNA from the British 1958 Birth Cohort collection, funded by the Medical Research Council grant G0000934 and the Wellcome Trust grant 068545/Z/02—funding for this project was provided by the Wellcome Trust under award 085475. NSECG was supported by the EU FP7 CHIBCHA grant, Wellcome Trust Centre for Human Genetics Core Grant 090532/Z/09Z, and CORGI was funded by Cancer Research UK. We thank Nick Martin, Dale Nyholt, and Anjali Henders for access to GWAS data from QIMR Controls. Recruitment of the QIMR controls was supported by the NHMRC. The University of Newcastle, the Gladys M Brawn Senior Research Fellowship scheme, The Vincent Fairfax Family Foundation, the Hunter Medical Research Institute, and the Hunter Area Pathology Service all contributed toward the costs of establishing the Hunter Community Study. The Bavarian Endometrial Cancer Study (BECS) was partly funded by the ELAN fund of the University of Erlangen. The Hannover-Jena Endometrial Cancer Study was partly supported by the Rudolf Bartling Foundation. The Leuven Endometrium Study (LES) was supported by the Verelst Foundation for endometrial cancer. The Mayo Endometrial Cancer Study (MECS) and Mayo controls (MAY) were supported by grants from the National Cancer Institute of United States Public Health Service (R01 CA122443, P30 CA15083, P50 CA136393, and GAME-ON the NCI Cancer Post-GWAS Initiative U19 CA148112), the Fred C and Katherine B Andersen Foundation, the Mayo Foundation, and the Ovarian Cancer Research Fund with support of the Smith family, in memory of Kathryn Sladek Smith. MoMaTEC received financial support from a Helse Vest Grant, the University of Bergen, Melzer Foundation, The Norwegian Cancer Society (Harald Andersens legat), The Research Council of Norway and Haukeland University Hospital. The Newcastle Endometrial Cancer Study (NECS) acknowledges contributions from the University of Newcastle, The NBN Children’s Cancer Research Group, Ms. Jennie Thomas, and the Hunter Medical Research Institute. RENDOCAS was supported through the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet (numbers: 20110222, 20110483, 20110141 and DF07015), The Swedish Labor Market Insurance (number 100069), and The Swedish Cancer Society (number 11 0439). The Cancer Hormone Replacement Epidemiology in Sweden Study (CAHRES, formerly called The Singapore and Swedish Breast/Endometrial Cancer Study; SASBAC) was supported by funding from the Agency for Science, Technology and Research of Singapore (A*STAR), the US National Institutes of Health, and the Susan G. Komen Breast Cancer Foundation. The WHI program is funded by the National Heart, Lung, and Blood Institute, the US National Institutes of Health, and the US Department of Health and Human Services (HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C). This work was also funded by NCI U19 CA148065-01. The Nurses’ Health Study (NHS) is supported by the NCI, NIH Grants Number UM1 CA186107, P01 CA087969, R01 CA49449, 1R01 CA134958, and 2R01 CA082838. We thank the participants and staff of the Nurses’ Health Study for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, and WY. We assume full responsibility for analyses and interpretation of these data. We also thank Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School. Finally, we also acknowledge Pati Soule and Hardeep Ranu for their laboratory assistance. The Connecticut Endometrial Cancer Study was supported by NCI, NIH Grant Number RO1CA98346. The Fred Hutchinson Cancer Research Center (FHCRC) is supported by NCI, NIH Grant Number NIH RO1 CA105212, RO1 CA 87538, RO1 CA75977, RO3 CA80636, NO1 HD23166, R35 CA39779, KO5 CA92002, and funds from the Fred Hutchinson Cancer Research Center. The Multiethnic Cohort Study (MEC) is supported by the NCI, NHI Grants Number CA54281, CA128008, and 2R01 CA082838. The California Teachers Study (CTS) is supported by NCI, NIH Grant Number 2R01 CA082838, R01 CA91019, and R01 CA77398, and contract 97-10500 from the California Breast Cancer Research Fund. The Polish Endometrial Cancer Study (PECS) is supported by the Intramural Research Program of the NCI. The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) is supported by the Extramural and the Intramural Research Programs of the NCI. The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts, HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C. This manuscript was prepared in collaboration with investigators of the WHI, and has been reviewed and/or approved by the Women’s Health Initiative (WHI). WHI investigators are listed at https://www.whi. org/researchers/Documents%20%20Write%20a%20Paper/WHI%20Investigator% 20Short%20List.pdf. The Breast Cancer Association Consortium (BCAC) is funded by Cancer Research UK (C1287/A10118, C1287/A12014). The Ovarian Cancer Association Consortium (OCAC) is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07), and the UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge. This research has been conducted using the UK Biobank Resource under applications 5122 and 9797. We gratefully acknowledge the TCGA endometrial cancer consortium for providing samples, tissues, data processing, and making data and results available. Additional funding for individual control groups is detailed in the Supplementary Information. Publisher Copyright: © 2018, The Author(s).

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Endometrial cancer is the most commonly diagnosed cancer of the female reproductive tract in developed countries. Through genome-wide association studies (GWAS), we have previously identified eight risk loci for endometrial cancer. Here, we present an expanded meta-analysis of 12,906 endometrial cancer cases and 108,979 controls (including new genotype data for 5624 cases) and identify nine novel genome-wide significant loci, including a locus on 12q24.12 previously identified by meta-GWAS of endometrial and colorectal cancer. At five loci, expression quantitative trait locus (eQTL) analyses identify candidate causal genes; risk alleles at two of these loci associate with decreased expression of genes, which encode negative regulators of oncogenic signal transduction proteins (SH2B3 (12q24.12) and NF1 (17q11.2)). In summary, this study has doubled the number of known endometrial cancer risk loci and revealed candidate causal genes for future study.

AB - Endometrial cancer is the most commonly diagnosed cancer of the female reproductive tract in developed countries. Through genome-wide association studies (GWAS), we have previously identified eight risk loci for endometrial cancer. Here, we present an expanded meta-analysis of 12,906 endometrial cancer cases and 108,979 controls (including new genotype data for 5624 cases) and identify nine novel genome-wide significant loci, including a locus on 12q24.12 previously identified by meta-GWAS of endometrial and colorectal cancer. At five loci, expression quantitative trait locus (eQTL) analyses identify candidate causal genes; risk alleles at two of these loci associate with decreased expression of genes, which encode negative regulators of oncogenic signal transduction proteins (SH2B3 (12q24.12) and NF1 (17q11.2)). In summary, this study has doubled the number of known endometrial cancer risk loci and revealed candidate causal genes for future study.

UR - http://www.scopus.com/inward/record.url?scp=85051554034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051554034&partnerID=8YFLogxK

U2 - 10.1038/s41467-018-05427-7

DO - 10.1038/s41467-018-05427-7

M3 - Article

C2 - 30093612

AN - SCOPUS:85051554034

VL - 9

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 3166

ER -

Identification of nine new susceptibility loci for endometrial cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this